Scotland To Improve Early Patient Access to ‘Ultra-Orphan’ Drugs
Executive Summary
Scotland is changing that way that medicines for very rare diseases are assessed by the health technology assessment body, the SMC. The changes include a new definition of “ultra-orphan medicine” and a new system for provisionally funding such products while more evidence is gathered on their effectiveness
You may also be interested in...
Scotland Launches New ‘Ultra-Orphan’ Assessment Pathway
The Scottish government is launching its new pathway for the assessment of “ultra-orphan” medicines by the HTA body, the Scottish Medicines Consortium, in an effort to speed up access to medicines for patients with very rare diseases
Scottish HTA Body Prepares For ‘Conditional Yes’ On Certain New Drugs
Scotland’s HTA body, the Scottish Medicines Consortium, is about to embark on a new system allowing it to give a “conditional yes” to medicines for which data may be limited at the time of marketing authorization. At the same time, changes are being implemented to the system for allowing patient access to drugs that have not been recommended by the SMC.
Biogen To Submit Spinraza To UK's NICE For SMA, While Australia Wants More Data
Biogen’s Spinraza for the rare disease spinal muscular atrophy is to be assessed by NICE, the UK HTA body for England and Wales. In the interim it will be made available under a managed access deal. The product is also being assessed by Australia’s PBAC, which has asked for more cost-effectiveness data and may require a reduction in the company’s proposed price.